Evidence map›Paper›PMID 42566913›Full record

ArticleAnnals of medicine2026

Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.

John Hanna, Hong Li, Ryan Brown, Zain Ali Burney, Kawther Abdallah, Diana Basali, Jason Valent, Christy Samaras, Faiz Anwer, Jack Khouri and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

John HannaDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID 0009-0006-0428-3505
Hong LiDepartment of Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Ryan BrownDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Zain Ali BurneyDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Kawther AbdallahDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Diana BasaliDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jason ValentDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Christy SamarasDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Faiz AnwerDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jack KhouriDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Shahzad RazaDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Willem Van HeeckerenDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Mazen HannaDepartment of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute; Cleveland Clinic, Cleveland, OH, USA.
J Emanuel FinetDepartment of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute; Cleveland Clinic, Cleveland, OH, USA.
Louis WilliamsDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Sandy MazzoniDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0001-7548-0705

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic light chain amyloidosis (AL) is a life-threatening disease in which dexamethasone (Dex) is a core therapy but is limited by cumulative toxicity. The optimal duration of Dex, particularly in the era of daratumumab (Dara)-based regimens, is uncertain.

methodsWe retrospectively analyzed 216 newly diagnosed AL amyloidosis patients (2017-2023). Dex exposure was categorized as limited (≤3 months) or prolonged (>3 months) using restricted cubic spline-derived associations with hematologic response kinetics. Outcomes included hematologic and organ response, toxicity, and overall survival.

resultsMedian Dex duration was 5.5 months and was similar by Dara use. Overall response rates exceeded 90% at 6 months in both Dex groups. Limited Dex was associated with higher rates of early deep hematologic response (VGPR or better 77.5 vs 56.5%,

conclusionsLimiting Dex exposure was associated with preserved efficacy and reduced toxicity. Prolonged Dex was associated with increased toxicity without improving overall hematologic or organ outcomes, supporting limited Dex duration in frontline AL amyloidosis therapy.

Indexed as

DexamethasoneImmunoglobulin Light-chain AmyloidosisAgedAged, 80 and overAntibodies, MonoclonalDrug Administration ScheduleFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, MonoclonaldaratumumabDexamethasonecorticosteroidshematologic responseLight chain amyloidosisorgan responsetoxicitytreatment duration

Identifiers

PMID42566913
PMCPMC13455702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.